Treatment of prostate cancer cell lines with the proteasome inhibitor NPI-0052 or the nitric oxide donor DETA/NO was shown, in vitro and in vivo, to reverse tumor cell EMT, migration, and invasion through, at least, RKIP-mediated NF-κB signaling inhibition and consequent suppression of the EMT inducers, Snail, vimentin, N-catherin, and fibronectin, and E-cadherin upregulation [130,131]. Here, NFKB1 is linked to prostate carcinoma.